Navigation Links
Premier Biomedical CEO Interviewed by The Wall Street Transcript
Date:4/30/2013

ST. PETERSBURG, Fla., April 30, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that President and Chief Executive Officer William Hartman was recently interviewed by The Wall Street Transcript (TWST), an independent investment publication of interviews with company CEOs, money managers, and Wall Street analysts.  The Bill Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (212) 952-7433 or via The Wall Street Transcript Online (http://www.twst.com/report/1975).

In the interview, Mr. Hartman discusses Premier Biomedical's revolutionary approach to medical treatment research and development.  Employing the Felder Doctrine™ developed by company co-founder Dr. Mitchell Felder , Premier Biomedical physically removes the pathophysiologic basis of a disease by processing the body fluids, such as blood for blood-borne diseases and cerebral spinal fluid for neurologic-based diseases.  Premier Biomedical has been successful in killing a cancer tumor in a test tube by simply eliminating the molecular compounds determined to be important in the growth factor of cancer.  The company's procedure takes only about 10 minutes, and within 24 hours the cancer tumor dies.  The process is currently being tested in mice.

In addition to the company's technology, Mr. Hartman spoke about Premier's collaborative agreements with the University of Texas at El Paso (UTEP) and the William Beaumont Army Medical Center (WBAMC).  He noted that through the scientific progress being made in cooperation with UTEP and WBAMC, the company's goal is to complete research and development and bring to market potential medications/procedures for its targeted diseases. 

Commenting on the interview with TWST, Mr. Hartman stated, "Exciting new technology developments are happening at Premier Biomedical and we are pleased to share our story with the prestigious readers of The Wall Street Transcript.  As a public company, we are becoming more active in our direct communications with the investment community through our own announcements and through important venues like TWST."

For a copy of the Biotechnology and Pharmaceuticals issue or for information on subscribing to The Wall Street Transcript, call (212) 952-7433 or visit The Wall Street Transcript Online (http://www.twst.com/report/1975).

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/ Lou Gehrig 's Disease), Blood Sepsis and Viremia, and Cancer.  Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis.  Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania.  The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."  www.premierbiomedicalinc.com

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995).  Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management.  Actual results could differ materially from current projections or implied results.  Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact
Premier Biomedical, Inc.
William A. Hartman , CEO
(814) 786-8849
info@premierbiomedicalinc.com


'/>"/>
SOURCE Premier Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Obesity Education Program To Premiere At American College of Physicians (ACP) Annual Meeting
2. iLab Solutions and Vanderbilt University Partner to Deliver a Premier Core Facility Management Solution
3. The RURO Flex™ Program - A Premier, Full Scale LIMS Made More Available
4. Une plainte contre une organisation du Prix Nobel pour diffamation et concurrence deloyale est déposée pour la première fois
5. Premier Biomedical Successfully Advances Cancer Research
6. Ekahau - A Preferred Provider of Real-Time Location Solutions - Is Awarded an Agreement with the Premier Healthcare Alliance
7. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
8. Premier Wen Visits Asymchems Tianjin Facility
9. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
10. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
11. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... TORONTO , Feb. 23, 2017 /PRNewswire/ - The ... Institute for Cancer Research (OICR) are pleased to report ... Series A financing, with Johnson & Johnson Innovation – ... investors include venture groups HealthCap, TPG Biotechnology Partners, and ... ...
(Date:2/23/2017)... SEATTLE , Feb. 23, 2017  Seattle,s upscale Capitol ... like a strange place for a head lice treatment salon ... nestled between a Tuscan restaurant and a French bistro on ... it,s perfect. "We aren,t just any old lice clinic, we ... to feel comfortable, and release some of the stigma associated ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):